Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply

Published:2024-06-06 Issue:2 Volume:60 Page:300-301
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

García María José¹^ORCID,Gisbert Javier P.²^ORCID,Chaparro María²^ORCID

Affiliation:

1. Gastroenterology and Hepatology Department, Hospital Universitario Marqués de Valdecilla, Grupo de Investigación Clínica y Traslacional en Enfermedades Digestivas, Instituto de Investigación Sanitaria Valdecilla (IDIVAL) Universidad de Cantabria Santander Spain

2. Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS‐Princesa), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) Universidad Autónoma de Madrid (UAM) Madrid Spain

Abstract

LINKED CONTENTThis article is linked to García et al papers. To view these articles, visit https://doi.org/10.1111/apt.17938 and https://doi.org/10.1111/apt.18056.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18104

Reference7 articles.

1. Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions

2. Effectiveness and safety of a third‐line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

3. Acute Severe Ulcerative Colitis Is Associated With an Increased Risk of Acute Pouchitis

4. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment

5. Acute severe ulcerative colitis management: unanswered questions and latest insights